Health Care and Genomics Industry Veteran, Kathy Hibbs, Esq. Joins 23andMe as Chief Legal and Regulatory Officer
April 2, 2014
23andMe Builds Out Leadership Team with Recent Appointments of New Vice President of Product and a New Vice President of Business Development and Strategy
Mountain View, Calif. – April 2, 2014 – 23andMe, the leading personal genetics company, today announced the appointment of Kathy Hibbs, Esq. as chief legal and regulatory officer. Hibbs brings more than 20 years of legal and management expertise in the clinical laboratory and medical device industries to 23andMe.
Hibbs will oversee the legal and regulatory functions of the company. Prior to joining 23andMe, Hibbs served as senior vice president and general counsel, responsible for the legal, regulatory and business development functions at Genomic Health, Inc. Hibbs has also held related posts at Monogram Biosciences Inc., and Varian Medical Systems, Inc. Hibbs is active in several industry groups, including the American Clinical Laboratory Association (ACLA), the Coalition for 21st Century Medicine and the Personalized Medicine Coalition (PMC). Hibbs holds a Juris Doctorate from the University of California, Hastings School of Law and a Bachelor of Arts in political science from the University of California, Riverside.
“We are extremely pleased to have Kathy join our leadership team at this important time in our company’s history,” said Andy Page, president of 23andMe. “We are confident that Kathy’s broad legal experience and diagnostic industry expertise will prove invaluable as we continue to enhance our service and expand our reach.”
“23andMe is at the forefront of unlocking the power of genetics,” said Kathy Hibbs, chief legal and regulatory officer for 23andMe. “I’m excited to join such a dynamic team at this pivotal point in the company’s growth.”
In addition, 23andMe has recently added top-tier talent to its leadership team with the appointment of Brad Kittredge as vice president of product and the appointment of Steve Schwartz as vice president of business development and strategy.
As vice president of product, Brad Kittredge is responsible for all elements of the 23andMe user experience, including product vision, design and management. Prior to joining 23andMe, Kittredge served as director of product management, health at Jawbone. Prior to his tenure at Jawbone, Kittredge held related positions at McKesson Corp. and was CEO and founder of ComplexDX. Kittredge holds an MBA from the Walter A. Haas School of Business; a master’s in public health management, health policy from the University of California, Berkeley; a master’s in international affairs from the University of California, San Diego; and a bachelor’s degree in psychology from the University of California, Berkeley.
As vice president of business development & strategy, Steve Schwartz leads 23andMe’s business development team, working with partners in life sciences, retail, academic medicine and health care. Schwartz is a health information technology veteran with more than 25 years of clinical laboratory, decision support and electronic health records industry experience. Before joining 23andMe, Schwartz was senior vice president of business development & strategy at Allscripts, a leading provider of electronic health records. Prior to Allscripts, Schwartz held related positions with Medifor Inc. and Laboratory Corporation of America Holdings (LabCorp). Schwartz holds degrees in business administration and psychology from the University of Washington.
“We are very excited about our recent hires and the growing management team at 23andMe,” said Anne Wojcicki, co-founder and CEO of 23andMe. “We have attracted incredible talent who share our passion for the company’s mission of revolutionizing health care by empowering consumers with direct access to their genetic information.”
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.